MX2017014731A - Eliminacion de linfocitos b como marcador diagnostico. - Google Patents

Eliminacion de linfocitos b como marcador diagnostico.

Info

Publication number
MX2017014731A
MX2017014731A MX2017014731A MX2017014731A MX2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A MX 2017014731 A MX2017014731 A MX 2017014731A
Authority
MX
Mexico
Prior art keywords
depleting agent
methods
cell
cell depleting
diagnostic marker
Prior art date
Application number
MX2017014731A
Other languages
English (en)
Inventor
Zugmaier Gerhard
Klinger Matthias
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of MX2017014731A publication Critical patent/MX2017014731A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En general, la presente invención hace referencia al campo de tratamientos médicos y marcadores diagnósticos, y, más específicamente, a métodos y usos para el tratamiento de leucemia linfocítica aguda (LLA) que involucran la administración de un agente de eliminación de linfocitos B. También se vislumbran usos y métodos para mantener o aumentar la cantidad de supervivientes a largo plazo de LLA. Los usos y métodos provistos en la presente comprenden la administración de un agente de eliminación de linfocitos B y/o el ajuste de la dosis o el régimen de tratamiento del agente de eliminación de linfocitos B, de forma que la cantidad de linfocitos B en la sangre de los pacientes tratados se mantenga o se reduzca a menos de un linfocito B/ml de suero en un período de tiempo predefinido.
MX2017014731A 2015-05-20 2016-05-19 Eliminacion de linfocitos b como marcador diagnostico. MX2017014731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562164278P 2015-05-20 2015-05-20
PCT/EP2016/061179 WO2016184931A1 (en) 2015-05-20 2016-05-19 B-cell depletion as a diagnostic marker

Publications (1)

Publication Number Publication Date
MX2017014731A true MX2017014731A (es) 2018-06-28

Family

ID=56119449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014731A MX2017014731A (es) 2015-05-20 2016-05-19 Eliminacion de linfocitos b como marcador diagnostico.

Country Status (6)

Country Link
EP (1) EP3298042A1 (es)
JP (1) JP7156793B2 (es)
AU (1) AU2016263464B2 (es)
CA (1) CA2980827A1 (es)
MX (1) MX2017014731A (es)
WO (1) WO2016184931A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580755A (en) 2007-04-03 2012-05-25 Micromet Ag Cross-species-specific cd3-epsilon binding domain
KR101695329B1 (ko) 2008-11-07 2017-01-23 암젠 리서치 (뮌헨) 게엠베하 소아 급성 림프구성 백혈병의 치료방법
LT2982696T (lt) 2008-11-07 2019-06-10 Amgen Research (Munich) Gmbh Ūmios limfoblastinės leukemijos gydymas

Also Published As

Publication number Publication date
JP7156793B2 (ja) 2022-10-19
WO2016184931A1 (en) 2016-11-24
JP2018517681A (ja) 2018-07-05
EP3298042A1 (en) 2018-03-28
AU2016263464B2 (en) 2021-12-23
AU2016263464A1 (en) 2018-01-04
CA2980827A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
TW201613887A (en) Antiproliferative compounds and methods of use thereof
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MY187540A (en) Compounds active towards bromodomains
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
PH12015502042B1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
TW201613578A (en) Pharmaceutical combinations
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12017500159B1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
MX2021001612A (es) Compuestos utiles en terapia del vih.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
MX2017014731A (es) Eliminacion de linfocitos b como marcador diagnostico.
MY186523A (en) Macrocyclic rip2 kinase inhibitors
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
UA104614U (uk) Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих
PL414619A1 (pl) Zastosowanie medyczne ekstraktu z ziela Centaurea borysthenica Gruner w leczeniu kardioprotekcyjnym
UA95571U (uk) Спосіб лікування переломів проксимального відділу стегнової кістки на фоні остеопорозу
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения
MX2017007990A (es) Métodos para reducir la agregación plaquetaria y tratar enfermedades cardiovasculares y otros transtornos médicos.